Farrar G Jane, Carrigan Matthew, Dockery Adrian, Millington-Ward Sophia, Palfi Arpad, Chadderton Naomi, Humphries Marian, Kiang Anna Sophia, Kenna Paul F, Humphries Pete
Institute of Genetics, School of Genetics and Microbiology, University of Dublin, Trinity College, Dublin 2, Ireland.
Research Foundation, Royal Victoria Eye and Ear Hospital, Dublin 2, Ireland.
Hum Mol Genet. 2017 Aug 1;26(R1):R2-R11. doi: 10.1093/hmg/ddx185.
While individually classed as rare diseases, hereditary retinal degenerations (IRDs) are the major cause of registered visual handicap in the developed world. Given their hereditary nature, some degree of intergenic heterogeneity was expected, with genes segregating in autosomal dominant, recessive, X-linked recessive, and more rarely in digenic or mitochondrial modes. Today, it is recognized that IRDs, as a group, represent one of the most genetically diverse of hereditary conditions - at least 260 genes having been implicated, with 70 genes identified in the most common IRD, retinitis pigmentosa (RP). However, targeted sequencing studies of exons from known IRD genes have resulted in the identification of candidate mutations in only approximately 60% of IRD cases. Given recent advances in the development of gene-based medicines, characterization of IRD patient cohorts for known IRD genes and elucidation of the molecular pathologies of disease in those remaining unresolved cases has become an endeavor of the highest priority. Here, we provide an outline of progress in this area.
尽管遗传性视网膜变性(IRDs)被分别归类为罕见疾病,但在发达国家,它们是登记在册的视力障碍的主要原因。鉴于其遗传性质,人们预期会有一定程度的基因间异质性,基因以常染色体显性、隐性、X连锁隐性方式分离,更罕见的是以双基因或线粒体模式分离。如今,人们认识到,作为一个群体,IRD是遗传条件中基因多样性最高的疾病之一——至少有260个基因与之相关,在最常见的IRD即色素性视网膜炎(RP)中已鉴定出70个基因。然而,对已知IRD基因外显子的靶向测序研究仅在约60%的IRD病例中鉴定出了候选突变。鉴于基于基因的药物开发的最新进展,对已知IRD基因的IRD患者队列进行特征分析以及阐明那些仍未解决的病例中的疾病分子病理学已成为最优先的工作。在此,我们概述了该领域的进展。